RESULTS	OXY-TDS 3.9 mg/day and TOL-LA 4 mg/day significantly reduced the number of daily incontinence episodes ( median change -3 OXY-TDS and -3 TOL-LA versus -2 placebo ; P < 0.05 ) , increased the average void volume ( median change 24 and 29 mL versus 5.5 mL , P < 0.01 ) , and improved quality of life ( incontinence impact questionnaire [ IIQ ] total score , P < 0.05 ; Urogenital Distress Inventory Irritative Symptom subscale , P < 0.05 ) compared with placebo .\